You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Impacting Type 2 Diabetes and Optimizing Patient Outcomes With GLP-1 Receptor Agonists

  • Authors: Vivian Fonseca, MD, FACE, Moderator; Lawrence Blonde, MD, FACP, FACE; Michael A. Nauck, Professor and Head Physician
  • CME Released: 10/18/2013
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 10/18/2014
Start Activity


Target Audience and Goal Statement

This activity was developed for endocrinologists, internists, primary care clinicians, and other healthcare professionals who manage patients with type 2 diabetes.

Management of type 2 diabetes is shifting to new treatment modalities that offer low risks of hypoglycemia and weight gain while effectively lowering blood glucose levels. GLP-1 receptor agonists can be used alone or in combination with other agents. This case-based continuing education program will explore the relative merits of GLP-1 receptor agonist therapy across the spectrum of patients with type 2 diabetes and provide a pathophysiologic and clinical rationale for the use of these agents. Faculty will present complex cases and review the rationale for and against different therapeutic options, and present data supporting why GLP-1 receptor agonists might be appropriate as part of mono- or combination-therapy strategies. Clinical scenarios and patient complexities that may require physicians to reconsider, re-evaluate, adjust therapy, or re-affirm their clinical decisions will be posed to the faculty for their expert opinions.

Upon completion of this activity, participants should be able to:

  1. Design pharmacologic strategies that optimize the use of GLP-1 receptor agonist therapy in comprehensive care plans for patients with diabetes based on stage of disease.
  2. Select glucose-lowering strategies based on patient factors that affect treatment success and patient safety.
  3. Summarize current and future trends of GLP-1 receptor agonist-based treatment strategies based on scientific and clinical evidence that address current unmet needs.


Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). Clinical and Patient Educators Association (CPEA) and Global Directions in Medicine do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

CPEA requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Authors

  • Vivian Fonseca, MD, FACE, Moderator

    Professor of Medicine and Pharmacology, Tullis Tulane Alumni Chair in Diabetes, Chief, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana

    Disclosures

    Disclosure: Investigator/Grant/Research Support to Tulane: Abbott, Eli Lilly & Company, Endo Barrier, Novo Nordisk Inc., Pan American Laboratories, Reata, Sanofi; Speaker/Consultant/Honorarium: Abbott, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Glaxo Smith Kline, Eli Lilly & Company, Novo Nordisk Inc., sanofi aventis, Pamlabs, Takeda.

  • Lawrence Blonde, MD, FACP, FACE

    Director, Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Diabetes, and Metabolic Diseases, Ochsner Medical Center, New Orleans, Louisiana

    Disclosures

    Disclosure: Grant/Research Support to Ochsner/Investigator: Eli Lilly & Company, Novo Nordisk Inc., Sanofi; Speaker/Honorarium: Amylin Pharmaceuticals Inc., Bristol-Myers Squibb/AstraZeneca, Janssen Pharmaceuticals Inc., Johnson & Johnson Diabetes Institute LLC, Merck & Co., Novo Nordisk Inc., Sanofi, Santarus; Consultant/Honorarium: Amylin Pharmaceuticals Inc., GlaxoSmithKline, Janssen Pharmaceuticals Inc., Merck & Co. Inc., Novo Nordisk Inc., Pfizer, Sanofi, Santarus.

  • Michael A. Nauck, Professor and Head Physician

    Professor and Head Physician, Diabeteszentrum Bad Lauterberg, Harz, Germany

    Disclosures

    Disclosure: Investigator/Grant/Research Support -- Monocentric investigator-initiated studies: Berlin Chemie AG, Eli Lilly & Co., Merck Sharp & Dohme GmbH, Novartis Pharma AG; Multicentric clinical studies: AstraZeneca, Boehringer lngelheim, GlaxoSmithKline, Lilly Deutschland GmbH, MetaCure Inc., Roche Pharma AG, Novo Nordisk Pharma GmbH, Tolerx Inc.; Advisory Board/Membership: Amylin Pharmaceuticals Inc., Berlin Chemie AG, Boehringer lngelheim, Eli Lilly & Co., Hoffmann-La Roche Ltd., lntarcia Therapeutics Inc., Janssen Global Services LLC, Merck Sharp & Oohme GmbH, Merck Sharp & Dohme Corp., Novo Nordisk Pharma GmbH, Sanofi-Aventis Pharma, Takeda, Versartis; Consultant/Honorarium: Amylin Pharmaceuticals Inc., AstraZeneca, Berlin Chemie AG, Boehringer lngelheim, Bristol Myers Squibb EMEA, Diartis Pharmaceuticals Inc., Eli Lilly & Co., Hoffmann-La Roche Ltd., GlaxoSmithKline LLC, Lilly Deutschland GmbH, MannKind Corp., Merck Sharp & Dohme GmbH, Novartis Pharma AG, Novo Nordisk Pharma GmbH, Novo Nordisk NS, sanofi-aventis Pharma, Takeda, Wyeth Research.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Deanna N. Schuly, Global Directions in Medicine: Nothing to disclose.

Katherine Mann, PharmD, Global Directions in Medicine: Nothing to disclose.

Kelly Enders, CPEA: Nothing to disclose.

Dennis Zanella, MD, CPEA: Nothing to disclose.


Accreditation Statements

This activity is jointly sponsored by Clinical and Patient Educators Association and Global Direction in Medicine.

    For Physicians

  • This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Clinical and Patient Educators Association and Global Directions in Medicine. Clinical and Patient Educators Association is accredited by the ACCME to provide continuing medical education for physicians.

    Clinical and Patient Educators Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Fee Information & Refund/Cancellation Policy:
    There is no fee to participate in this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Impacting Type 2 Diabetes and Optimizing Patient Outcomes With GLP-1 Receptor Agonists

Authors: Vivian Fonseca, MD, FACE, Moderator; Lawrence Blonde, MD, FACP, FACE; Michael A. Nauck, Professor and Head PhysicianFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 10/18/2013

Valid for credit through: 10/18/2014

processing....

This CME activity is based on the slides and lectures presented by the faculty at the symposium, Impacting Type 2 Diabetes and Optimizing Patient Outcomes With GLP-1 Agonists, on June 23, 2013, at the Hilton Chicago hotel, Chicago, Illinois

Contents of This CME Activity

All sections of this activity are required for credit.

Part 1: Using GLP-1 Receptor Agonists in Early-Stage Diabetes and Special Circumstances
Part 2: GLP-1 Receptor Agonists in Patients With Established Diabetes
Part 3: Treatment Intensification to Improve Glycemic Control While Minimizing Weight Gain and Hypoglycemia: Use of GLP-1 Receptor Agonists
Part 4: Panel Discussion